Apr 23, 2021

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness

Contributor Leukemia

Behind the paper

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness

Alexander Grandits

Apr 01, 2021

Comorbidity in chronic lymphocytic leukemia

Contributor Leukemia

Behind the paper

Comorbidity in chronic lymphocytic leukemia

+2

Emelie Curovic Rotbain and 2 others

Feb 18, 2021

Contributor Leukemia

Double mutated myeloproliferative neoplasms: rare but distinctive

+1

Barbara Mora and 1 other

Jan 13, 2021

Contributor Leukemia

Behind the paper, COVID-19

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui

Jan 13, 2021

Co-mutations, mutation order and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms

Contributor Blood Cancer Leukemia Nature

Behind the paper

Co-mutations, mutation order and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms

Gabriele Todisco

Jan 11, 2021

BCL-2 inhibition synergizes with glutamine depletion in complex karyotype AML

Contributor Leukemia

Behind the paper

BCL-2 inhibition synergizes with glutamine depletion in complex karyotype AML

+1

Dominique Bollino and 1 other

Jan 05, 2021

Chromosomes on the move

Contributor Leukemia

Behind the paper

Chromosomes on the move

Martin Kaiser

Dec 27, 2020

Contributor Leukemia

Tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

Franck Morschhauser

Dec 22, 2020

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

Contributor Leukemia

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

Montserrat Estruch

Dec 11, 2020

Contributor Leukemia

Behind the paper

FAM122A, a critical factor for maintaining the functions of hematopoietic stem cells

Ying Huang and Manhua Liu

+2

Manhua Liu and 2 others

Dec 09, 2020

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Contributor Leukemia

Behind the paper

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

Cosimo Lobello

Dec 01, 2020

Contributor Leukemia

Behind the paper

New players against AML: novel targets with preclinical potencies

Better understanding of AML biology and survival tactics has facilitated a wave of newly approved drugs against AML and also revealed a range of targets to be exploited for treatment. In our review, we discuss what these new targets are and how targeting them in combination might be beneficial.

Ramya Nair

Nov 21, 2020

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

Contributor Leukemia

Behind the paper

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

Upasana Sunil Arvindam

Nov 16, 2020

p190-BCR-ABL Isoform in CML: A Minor breakpoint and A Major Impact

Contributor Leukemia

Behind the paper

p190-BCR-ABL Isoform in CML: A Minor breakpoint and A Major Impact

+1

Shady Adnan-Awad and 1 other

Nov 12, 2020

Stage-specific trends in primary therapy and survival in follicular lymphoma

Contributor Leukemia

Behind the paper

Stage-specific trends in primary therapy and survival in follicular lymphoma

Manette Dinnessen

Nov 09, 2020

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice

Contributor Leukemia

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice

Daniele

Nov 09, 2020

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Contributor Leukemia

Behind the paper

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Christoph Rummelt

Nov 05, 2020

Donor derived CD19 CAR-T cell for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Contributor Leukemia

Behind the paper

Donor derived CD19 CAR-T cell for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Xi Zhang

Oct 30, 2020

Phosphoproteomic profiling in leukaemia illuminates treatment targets that are invisible to genomics, but how do we bring them to the clinic...

Contributor Leukemia

Behind the paper

Phosphoproteomic profiling in leukaemia illuminates treatment targets that are invisible to genomics, but how do we bring them to the clinic...

+3

Matthew D. Dun and 3 others

Oct 23, 2020

Nature Portfolio Cancer Community

Leukemia

A new way to improve immune checkpoint blockade therapy in CLL

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness

Comorbidity in chronic lymphocytic leukemia

Double mutated myeloproliferative neoplasms: rare but distinctive

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Co-mutations, mutation order and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms

BCL-2 inhibition synergizes with glutamine depletion in complex karyotype AML

Chromosomes on the move

Tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy

FAM122A, a critical factor for maintaining the functions of hematopoietic stem cells

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma

New players against AML: novel targets with preclinical potencies

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

p190-BCR-ABL Isoform in CML: A Minor breakpoint and A Major Impact

Stage-specific trends in primary therapy and survival in follicular lymphoma

Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Donor derived CD19 CAR-T cell for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Phosphoproteomic profiling in leukaemia illuminates treatment targets that are invisible to genomics, but how do we bring them to the clinic...

Register to Nature Portfolio Cancer Community